India’s Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN) are seeking regulatory approval to develop affordable anti-obesity pills as the country faces a mounting obesity crisis, Mint reported on Monday, citing documents and a person familiar with the matter.
The Drugs Controller General of India (DCGI) has cleared Sun Pharma to conduct a large-scale Phase III trial for its semaglutide tablets, while Lupin has received approval to begin a bioequivalence study to show its generic version performs similarly to the original, Mint said.
Currently, anti-obesity drugs such as Novo Nordisk’s (CSE:NOVOb) Wegovy and Eli Lilly’s (NYSE:LLY) Mounjaro remain costly and largely limited to injections, reducing accessibility for Indian patients.
A Lancet study has projected India could have 450 million overweight and obese adults by 2050. Experts cited by Mint said generics could bring costs down but warned against misuse, stressing the need for strict medical supervision and regulatory safeguards.
Source :
https://www.investing.com/news/stock-market-news/sun-pharma-lupin-push-for-affordable-antiobesity-pills-in-india--mint-4228021
